Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells
- 22 November 2005
- journal article
- Published by Springer Nature in Leukemia
- Vol. 19 (12) , 2281-2288
- https://doi.org/10.1038/sj.leu.2403977
Abstract
Overexpression of the detoxifying enzyme cytidine deaminase (CDD) renders normal and leukemic hematopoietic cells resistant to cytarabine (1--D-arabinofuranosylcytosine), and studies on murine cells have suggested transgenic CDD overexpression as a way to reduce the substantial myelotoxicity induced by the deoxycytidine analogs cytarabine and gemcitabine (2',2'-difluorodeoxycytidine). We now have investigated CDD (over-)expression in the human hematopoietic system. Retroviral gene transfer significantly increased the resistance of CDD-transduced cord blood and peripheral blood-derived progenitor cells for doses ranging from 20–100 nM cytarabine and 8–10 nM gemcitabine. Protection was observed for progenitors of erythroid as well as myeloid differentiation, though the degree of protection varied for individual drugs. In addition, significant selection of CDD-transduced cells was obtained after a 4-day culture in 30–100 nM cytarabine. Thus, our data demonstrate that overexpression of CDD cDNA results in significant protection of human progenitors from cytarabine- as well as gemcitabine-induced toxicity, and allows in vitro selection of transduced cells. This strongly argues for a potential therapeutic role of CDD gene transfer in conjunction with dose-intensive cytarabine- or gemcitabine-containing chemotherapy regimen.Keywords
This publication has 30 references indexed in Scilit:
- Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion geneMolecular Therapy, 2004
- Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cellsGene Therapy, 2002
- Novel Bicistronic Retroviral Vector Expressingγ-Glutamylcysteine Synthetase and the Multidrug Resistance Protein 1 (MRP1) Protects Cells from MRP1-Effluxed Drugs and Alkylating AgentsHuman Gene Therapy, 2001
- Marrow protection – transduction of hematopoietic cells with drug resistance genesCytotherapy, 2001
- Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cellsGene Therapy, 2001
- Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectorsCancer Gene Therapy, 2000
- Expression of a Novel Double-Mutant Dihydrofolate Reductase-Cytidine Deaminase Fusion Gene Confers Resistance to Both Methotrexate and Cytosine ArabinosideHuman Gene Therapy, 1999
- Retroviral transfer and long-term expression of human cytidine deaminase cDNA in hematopoietic cells following transplantation in miceGene Therapy, 1998
- Drug resistance to 5-aza-2 ′ -deoxycytidine, 2 ′ ,2 ′ -difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cellsCancer Chemotherapy and Pharmacology, 1998
- Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease.The Journal of Experimental Medicine, 1993